Corrigendum To: Cardiovascular Actions and Therapeutic Potential of Tanshinone IIA [atherosclerosis 220 (2012) 3–10]

Si Gao,Zhi-Ping Liu,Hong Li,Peter J. Little,Peiqing Liu,Suowen Xu
DOI: https://doi.org/10.1016/j.atherosclerosis.2012.01.014
IF: 5.3
2012-01-01
Atherosclerosis
Abstract:In the above article Fig. 1 should have appeared as below. Cardiovascular actions and therapeutic potential of tanshinone IIAAtherosclerosisVol. 220Issue 1PreviewTanshinone IIA (TS), a pharmacologically active component isolated from the rhizome of the Chinese herb Salvia miltiorrhiza Bunge (Danshen), has been clinically used in Asian countries for the prevention and treatment of coronary heart disease. Recently, the pharmacological properties of TS in the cardiovascular system have attracted great interest. Emerging experimental studies and clinical trials have demonstrated that TS prevents atherogenesis as well as cardiac injury and hypertrophy. In atherosclerosis, TS acts by inhibiting LDL oxidation, monocyte adhesion to endothelium, smooth muscle cell migration and proliferation, macrophage cholesterol accumulation, proinflammatory cytokine expression and platelet aggregation. Full-Text PDF
What problem does this paper attempt to address?